Pharvaris (PHVS) Change in Receivables (2020 - 2026)
Pharvaris' (PHVS) quarterly Change in Receivables came in at -$335027.6 in Q1 2026, down 154.22% YoY from $617925.2 in Q1 2025, and up 26.04% on a QoQ basis from -$453000.3 in Q4 2025.
Analysis
Pharvaris (PHVS) Change in Receivables (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Change in Receivables data on file, last reported at -$335027.6 in Q1 2026.
- Quarterly Change in Receivables fell 154.22% year-over-year to -$335027.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$575873.1 (down 141.79% YoY) and the FY2025 annual result came in at -$374350.5, down 907.9% from the prior year.
- Change in Receivables climbed to -$335027.6 in Q1 2026, from -$453000.3 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $52.5 billion in Q2 2023 to a low of -$52.4 billion in Q3 2023.
- A 5-year average of $919811.0 and a median of -$12465.8 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 14582576.89% in 2023, down 72003334.17% in 2023.
- Tracing PHVS's Change in Receivables over 5 years: stood at $22127.1 in 2022, then plunged by 657.61% to -$123382.3 in 2023, then jumped by 262.44% to $200423.6 in 2024, then sank by 326.02% to -$453000.3 in 2025, then increased by 26.04% to -$335027.6 in 2026.
- The last three Change in Receivables figures came in at -$335027.6 (Q1 2026), -$453000.3 (Q4 2025), and $153880.4 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -82,183.63 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -82,183.63 |
| Mar 31, 2026 | -335,027.60 |
| Dec 31, 2025 | -453,000.34 |
| Sep 30, 2025 | 153,880.38 |
| Jun 30, 2025 | 58,274.42 |
| Mar 31, 2025 | -131,787.45 |
| Dec 31, 2024 | 200,423.62 |
| Sep 30, 2024 | 100.80 Bn |
| Jun 30, 2024 | -98.84 Bn |
| Mar 31, 2024 | 65,667.31 |
| Dec 31, 2023 | -123,382.33 |
| Sep 30, 2023 | -52.44 Bn |
| Jun 30, 2023 | 52.45 Bn |
| Mar 31, 2023 | -12,465.79 |
| Dec 31, 2022 | 22,127.12 |
| Sep 30, 2022 | -371.20 Bn |
| Jun 30, 2022 | 392.84 Bn |
| Mar 31, 2022 | 34,865.42 |
| Dec 31, 2021 | -77,460.56 |
| Sep 30, 2021 | 94,812.34 |